MIS 416
Alternative Names: MIS-416Latest Information Update: 28 Dec 2022
At a glance
- Originator Virionyx
- Developer Amplia Therapeutics Limited; Innate Immunotherapeutics
- Class Adjuvants; Anti-infectives; Antineoplastics; Neuroprotectants
- Mechanism of Action Immunomodulators; Immunostimulants; NOD2 protein agonists; NOD2 protein modulators; Toll-like receptor 9 agonists; Toll-like receptor 9 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer; Infections; Multiple sclerosis; Solid tumours
Most Recent Events
- 28 Dec 2022 Discontinued - Phase-I for Solid tumours (Combination therapy, Second-line therapy or greater) in Japan (Parenteral) (Amplia Therapeutics pipeline, December 2022)
- 28 Dec 2022 Discontinued - Preclinical for Cancer in New Zealand (Parenteral) (Amplia Therapeutics pipeline, December 2022)
- 28 Dec 2022 Discontinued - Preclinical for Infections in New Zealand (Parenteral) (Amplia Therapeutics pipeline, December 2022)